Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing ...

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular ...

Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics, where during his 13 years he played a pivotal part in building out their discovery ...

China's first national-level onshore shale oil demonstration zone has reached its annual crude output target of 1.7 million ...

The University of Delaware’s David Martin, Karl W. and Renate Böer Chair in the Department of Materials Science and Engineering, has been named to the National Academy of Inventors (NAI) 2025 Class of ...

Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia December 11, 2025 10:00 AM ESTCompany ...

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major ...

Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today ...

Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced ...

A new analysis by the World Health Organization reaffirmed there is no link between vaccines and autism—contrary to theories ...